NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for
WP45338
Phase 3 small_molecule active
Quick answer
NovoSeven 8 mg (400 KIU) powder and solvent for solution for injection, Voncento 250 IU FVIII / 600 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ADVATE 1 500 IU/2 ml powder and solvent for solution for injection, Voncento 500 IU FVIII / 1200 IU VWF (5 ml solvent) powder and solvent for solution for injection/infusion, ELOCTA 500 IU Powder and solvent for solution for injection, ELOCTA 750 IU Powder and solvent for solution for injection, ELOCTA 2000 IU Powder and solvent for for Type 3 Von Willebrand Disease is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Type 3 Von Willebrand Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active